Clinical Goals and Barriers to Effective Psoriasis Care

Strober, Bruce; Walt, Joelle M. van der; Armstrong, April W.; Bourcier, Marc; Carvalho, André Vicente Esteves de; Chouela, Edgardo; Cohen, Arnon D.; Cruz, C.; Ellis, Charles N.; Finlay, Andrew Y.; Gottlieb, Alice B.; Guðjónsson, Jóhann E.; Iversen, Lars; Kleyn, C. Elise; Leonardi, Craig L.; Lynde, Charles; Ryan, Caitriona; Theng, Colin; Valenzuela, Fernando; Vender, Ronald; Wu, Jashin J.; Young, Helen; Kimball, Alexa B.

doi:10.1007/s13555-018-0279-5

Cited by 70 publications

(70 citation statements)

References 84 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…3 Treatment goals agreed between the patient and the physician are also key to ongoing patient adherence. 13 Effective strategies can be put in place by physicians to help patients to achieve therapeutic outcomes: positive patient-physician relationships, patient education, follow up visits or calls, and patient participation in treatment decisions. 14 In this context, the Topical Treatment Optimization Programme (TTOP) study, which was a large European investigator-initiated study, was designed to improve adherence to treatment in psoriasis.…”

Section: Discussionmentioning

confidence: 99%

<p>Spotlight on Topical Long-Term Management of Plaque Psoriasis</p>

Carrascosa

Theng²,

Thaçi

2020

CCID

View full text Add to dashboard Cite

During the 28th Congress of the European Academy of Dermatology and Venereology (EADV) held in Madrid in October 2019, an industry hub was dedicated to the long-term management of psoriasis. Psoriasis is a systemic inflammatory disease primarily involving the skin that affects up to 4% of the European population, the majority of whom present with chronic plaque psoriasis. Topical therapies are well established in the first-line treatment of psoriatic plaque flares. Nevertheless, as psoriasis is a chronic disease, long-term control should be considered. The aim of the session was to provide expert opinion on the benefit of long-term maintenance therapy in chronic plaque psoriasis and introduce the concept of pro-active management to decrease the number of relapses and improve patient quality of life. The current guidelines and recommendations were reviewed, as well as the available data on published clinical trials. There is still an important role for topical therapy in psoriasis and current recommendations suggest a maintenance regimen for psoriasis. Adherence optimization and proactive management of relapse can be key factors for obtaining clinical outcomes in topical long-term therapy. Calcipotriol/betamethasone dipropionate foam is the only topical formulation with long-term data as a twice-weekly proactive treatment approach for up to 52 weeks for chronic plaque psoriasis.

show abstract

Section: Discussionmentioning

confidence: 99%

<p>Spotlight on Topical Long-Term Management of Plaque Psoriasis</p>

Carrascosa

Theng²,

Thaçi

2020

CCID

View full text Add to dashboard Cite

show abstract

“…We identified the following factors as important drivers of adherence to prescribed therapies: frequency of treatment application, treatment formulation, need for multiple therapies, fast onset of action, corticosteroid-phobia, long-term psychological burden of chronic treatment, low quality of life, topical fatigue and treatment goals. It is important that treatment goals are agreed between the patient and physician to ensure ongoing patient adherence (46). Effective strategies that physicians can utilize to help patients achieve optimal therapeutic outcomes include positive patientphysician relationships, patient education, follow-up visits or calls, and patient participation in treatment decisions (47).…”

Section: Low Patient Adherencementioning

confidence: 99%

“…To help address these concerns, efficacy and safety data for long-term topical use are needed, as well as educational programs that counteract misinformation. Physicians and nurses are in a key position to directly influence a patient's perception of psoriasis and to clearly explain the importance of continuing treatment (5); it is also important that healthcare professionals work with patients to establish clear long-term treatment goals (46).…”

Section: Tachyphylaxismentioning

confidence: 99%

Long-term topical management of psoriasis: the road ahead

Segaert

Calzavara‐Pinton

Cueva

et al. 2020

Journal of Dermatological Treatment

View full text Add to dashboard Cite

Topical therapies have been available for the treatment of psoriasis for several decades. Despite this and the availability of several types of topicals, with varying potency, and numerous vehicles of administration, the majority of clinical data and guidance is on short-term use in the management of psoriasis. The aim of this manuscript is to review the unmet needs that exist in the long-term management of psoriasis and provide the dermatology community with an understanding that a treatment regimen with topical therapies could be the best treatment option at least for some phases of this chronic relapsing disease. We present a 'call to action' on the need for clinical alignment on terminology in the field and recommend the term 'long-term management' be adopted as the most appropriate in the context of this manuscript. This expert opinion report provides a detailed review of the limited evidence available regarding long-term use of topical therapies for the management of psoriasis, alongside our key considerations and recommendations to assist dermatologists with the implementation of topicals as part of long-term management strategies. Long-term management should be considered mandatory to ensure patients receive appropriate proactive treatment which may help optimize adherence and long-term outcomes.

show abstract

“…Estimates suggest that psoriasis affects as many as 7.5 million people in the USA and more than 125 million people worldwide [4][5][6]. Within this population, approximately 80% of patients have mild-to-moderate and/or localized disease that can be successfully treated with topical medications; approximately 20% of patients have moderate-to-severe disease that often requires treatment with systemic medications [7][8][9].…”

Section: Epidemiologymentioning

confidence: 99%

PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis

Gold

Alonso‐Llamazares

Lacour³

et al. 2020

Adv Ther

View full text Add to dashboard Cite

Background: Psoriasis vulgaris is commonly treated with topical corticosteroids and vitamin D analogues. Although potent and superpotent topical corticosteroids are very effective at clearing psoriasis, with short-term reactive treatment durations, symptoms usually recur after treatment discontinuation, necessitating long-term disease management strategies. A foam formulation of calcipotriol and betamethasone dipropionate (Cal/BD foam), consisting of calcipotriol 50 lg/g and betamethasone dipropionate 0.5 mg/g, is approved for the daily treatment of psoriasis for up to 4 weeks. Here, we describe a clinical trial protocol for evaluating the long-term safety and efficacy of twice-weekly Cal/BD foam as a proactive topical maintenance therapy for plaque psoriasis for up to 52 weeks. Objective: The aim of this trial was to evaluate the safety and efficacy of Cal/BD foam when Digital Features To view digital features for this article, go to

show abstract

Clinical Goals and Barriers to Effective Psoriasis Care

Cited by 70 publications

References 84 publications

<p>Spotlight on Topical Long-Term Management of Plaque Psoriasis</p>

<p>Spotlight on Topical Long-Term Management of Plaque Psoriasis</p>

Long-term topical management of psoriasis: the road ahead

PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis

Contact Info

Product

Resources

About